The Vanessa Moss Prize: celebrating research into cancer health disparities
Prof Robin Foà talks to ecancer about the latest in Philadelphia chromosome-positive ALL (Ph+ ALL).
He begins by stating that the changes have been quite dramatic, going on to say that Ph+ ALL was the worst sub-group of leukaemias in terms of prognosis, for both adults and children. The only chance of a cure was an allogeneic stem cell transplant, when doable.
Prof Foà then goes on to explain how the incidents of Ph+ ALL increases with age. About 1 in 2 B-lineage ALL patients over the age of 50-60 years old.
He concludes by saying maybe some patients in the future can be managed without chemo or without transplant, referring to other research he adds if patients do not have additional genetic abnormalities at diagnosis or the MRD is repeatedly negative these patients will not receive a transplant even with a sibling donor. So, he hopes it can be proven that at least a portion of patients can be managed and possibly cured without systemic chemo or transplant.
The Vanessa Moss Prize: celebrating research into cancer health disparities
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
African oncologists interaction with pharmaceutical industry